MA48459B1 - Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase - Google Patents

Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase

Info

Publication number
MA48459B1
MA48459B1 MA48459A MA48459A MA48459B1 MA 48459 B1 MA48459 B1 MA 48459B1 MA 48459 A MA48459 A MA 48459A MA 48459 A MA48459 A MA 48459A MA 48459 B1 MA48459 B1 MA 48459B1
Authority
MA
Morocco
Prior art keywords
methods
benzotriazole derivatives
oxygenase inhibitors
trisubstituted benzotriazole
dihydroorotate oxygenase
Prior art date
Application number
MA48459A
Other languages
English (en)
Other versions
MA48459A (fr
Inventor
Subramanya Hosahalli
Kavitha Nellore
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/494,820 external-priority patent/US9937155B2/en
Priority claimed from US15/899,707 external-priority patent/US20180369206A1/en
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of MA48459A publication Critical patent/MA48459A/fr
Publication of MA48459B1 publication Critical patent/MA48459B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de traitement d'un cancer chez un sujet et d'inhibition de la croissance tumorale, de la métastase ou d'une activité enzymatique de dihydroorotate oxygénase d'une tumeur ou d'une cellule cancéreuse. Au moins un dérivé de benzotriazole trisubstitué de formule (i) est administré au sujet ou est mis en contact avec la cellule cancéreuse. Les composés de formule (i) ont des substituants r1, r2 et r3 qui ont les significations données dans la description, et des sels pharmaceutiquement acceptables de ceux-ci.
MA48459A 2017-04-24 2018-04-19 Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase MA48459B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/494,820 US9937155B2 (en) 2013-02-25 2017-04-24 Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US15/899,707 US20180369206A1 (en) 2017-04-24 2018-02-20 Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
PCT/IB2018/052710 WO2018197997A1 (fr) 2017-04-24 2018-04-19 Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase

Publications (2)

Publication Number Publication Date
MA48459A MA48459A (fr) 2020-03-04
MA48459B1 true MA48459B1 (fr) 2021-09-30

Family

ID=65803213

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48459A MA48459B1 (fr) 2017-04-24 2018-04-19 Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase

Country Status (27)

Country Link
US (2) US12290507B2 (fr)
EP (2) EP3915557A1 (fr)
JP (3) JP7225114B2 (fr)
KR (2) KR102756047B1 (fr)
CN (1) CN110662539B (fr)
AU (1) AU2018260390B2 (fr)
CA (1) CA3060390A1 (fr)
CY (1) CY1124702T1 (fr)
DK (1) DK3615027T3 (fr)
EA (1) EA201992528A1 (fr)
ES (1) ES2889100T3 (fr)
HR (1) HRP20211462T1 (fr)
HU (1) HUE056485T2 (fr)
IL (1) IL270066B2 (fr)
LT (1) LT3615027T (fr)
MA (1) MA48459B1 (fr)
MD (1) MD3615027T2 (fr)
MX (1) MX2019012640A (fr)
PH (1) PH12019502402A1 (fr)
PL (1) PL3615027T3 (fr)
PT (1) PT3615027T (fr)
RS (1) RS62519B1 (fr)
SG (1) SG11201909718QA (fr)
SI (1) SI3615027T1 (fr)
SM (1) SMT202100553T1 (fr)
TW (1) TWI821180B (fr)
UA (1) UA129244C2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) * 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma
KR102514860B1 (ko) * 2020-12-01 2023-03-29 한국과학기술연구원 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2102367T3 (es) 1990-05-18 1997-08-01 Hoechst Ag Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
MX9708620A (es) 1995-05-10 1998-02-28 Pfizer Combinacion de metotrexate y tenidap para el tratamiento de artritis reumatoide.
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
WO2001024785A2 (fr) 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Composes servant a traiter des maladies d'origine virale
WO2003006424A1 (fr) 2001-07-10 2003-01-23 4Sc Ag Nouveaux composes utilises comme agents anti-inflammatoires, immunomodulateurs et anti-proliferatoires
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
ATE474833T1 (de) 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
DE102005049953A1 (de) 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
WO2008028860A1 (fr) 2006-09-08 2008-03-13 F. Hoffmann-La Roche Ag Modulateurs de kinases à base de benzotriazole
WO2010081898A1 (fr) 2009-01-19 2010-07-22 Neurosearch A/S Nouveaux dérivés de benzotriazole utiles pour le traitement de troubles du snc
EP2230232A1 (fr) 2009-03-13 2010-09-22 Almirall, S.A. Sels adjuvants de trométhamine dotés de dérivés d'acide azabiphénylaminobenzoïque en tant qu'inhibiteurs de la DHOD
EP2228367A1 (fr) 2009-03-13 2010-09-15 Almirall, S.A. Sels adjuvants d'amines contenant des groupes hydroxyle et/ou carbonyle avec des dérivés d'acides aminonicotiques en tant qu'inhibiteurs de la DHODH
US9316632B2 (en) 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
MY159575A (en) 2009-04-02 2017-01-13 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
ES2642109T3 (es) 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
WO2011143160A2 (fr) * 2010-05-10 2011-11-17 The Johns Hopkins University Inhibiteur métabolique contre des tumeurs ayant une mutation de l'idh
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
WO2013049112A1 (fr) 2011-09-27 2013-04-04 Emory University Détection de biomarqueurs à l'aide de résonance magnétique
CN103965133B (zh) 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
RS57962B1 (sr) * 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US11730716B2 (en) 2014-05-08 2023-08-22 Kiora Pharmaceuticals Gmbh Compounds for treating ophthalmic diseases and disorders
US11096934B2 (en) 2015-09-01 2021-08-24 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
JP6961879B2 (ja) 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (fr) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Polythérapie
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
WO2019012030A1 (fr) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteur de dhodh et inhibiteur de chk1 pour le traitement du cancer
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
WO2020109625A1 (fr) 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Traitement combiné du lymphome primaire du système nerveux central
JOP20210147A1 (ar) 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه
US12582667B2 (en) 2019-09-27 2026-03-24 The Rockefeller University Compositions and methods to treat metastatic gastrointestinal cancer
CA3184024A1 (fr) 2020-06-24 2021-12-30 Les Laboratoires Servier Utilisation d'un compose inhibiteur de dhodh en polytherapie anticancereuse
WO2021262874A1 (fr) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Utilisation d'un composé inhibiteur de dhodh en polythérapie anticancéreuse
ES3063941T3 (en) 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma

Also Published As

Publication number Publication date
JP7225114B2 (ja) 2023-02-20
NZ758333A (en) 2025-10-31
KR102678263B1 (ko) 2024-06-24
PT3615027T (pt) 2021-09-24
US12290507B2 (en) 2025-05-06
MA48459A (fr) 2020-03-04
PL3615027T3 (pl) 2022-01-03
EP3615027B1 (fr) 2021-07-14
AU2018260390B2 (en) 2024-05-02
SMT202100553T1 (it) 2021-11-12
LT3615027T (lt) 2021-10-25
IL270066A (fr) 2019-12-31
UA129244C2 (uk) 2025-02-26
CN110662539B (zh) 2023-08-15
MX2019012640A (es) 2020-12-11
JP2020517654A (ja) 2020-06-18
IL270066B2 (en) 2023-10-01
MD3615027T2 (ro) 2021-11-30
HRP20211462T1 (hr) 2021-12-24
RS62519B1 (sr) 2021-11-30
AU2024205090A1 (en) 2024-08-15
CN110662539A (zh) 2020-01-07
BR112019022331A2 (pt) 2020-05-26
CY1124702T1 (el) 2022-07-22
US20260097019A1 (en) 2026-04-09
JP2023022252A (ja) 2023-02-14
EA201992528A1 (ru) 2020-02-28
HUE056485T2 (hu) 2022-02-28
DK3615027T3 (da) 2021-08-30
TWI821180B (zh) 2023-11-11
EP3915557A1 (fr) 2021-12-01
KR20240105481A (ko) 2024-07-05
IL270066B1 (en) 2023-06-01
ES2889100T3 (es) 2022-01-11
US20220241246A1 (en) 2022-08-04
SI3615027T1 (sl) 2021-12-31
CA3060390A1 (fr) 2018-11-01
AU2018260390A1 (en) 2019-11-07
EP3615027A1 (fr) 2020-03-04
PH12019502402A1 (en) 2021-01-25
TW201902880A (zh) 2019-01-16
KR102756047B1 (ko) 2025-01-15
JP2025156453A (ja) 2025-10-14
SG11201909718QA (en) 2019-11-28
KR20190140005A (ko) 2019-12-18

Similar Documents

Publication Publication Date Title
MA48459B1 (fr) Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
JOP20240084A1 (ar) مركبات الكينولين كمثبطات لـ kras
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA38461B1 (fr) Inhibiteurs de la voie de la kynurénine
MA34342B1 (fr) Dérivés de la pipéridinone en tant qu'inhibiteurs de mdm2 pour le traitement du cancer
MA55890B1 (fr) Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA33330B1 (fr) Quinazolines substituées comme fongicides
MA38454A1 (fr) Inhibiteurs de protéines kinases
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
PH12022552680A1 (en) Cd38 inhibitors
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
MA34385B1 (fr) Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes)
MA35643B1 (fr) Inhibiteur de cetp d'oxazolidinone bicyclique condensée
TN2015000347A1 (fr) Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles
MA44021B1 (fr) Composés antitumoraux
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
WO2023073013A8 (fr) Inhibiteurs de lrrk2
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA40605B1 (fr) Composé pyrazolothiazole et médicament
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MA38275B1 (fr) Hétérocycles azotés saturés et n-acylés potentialisant l'activité d'un antibiotique actif contre les mycobactéries
EA201690818A1 (ru) Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов